HEALTHCARE GLOB ENT Latest Share Price (HCG)
TODAY IN ONE LINE
HCG fell 1.0% on light volume, in line with Nifty's -0.3% move, supported by recent strong earnings.
With a market cap of ₹10,356.35 Cr., it trades at a P/E of 453.37. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
HEALTHCARE GLOB ENT flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Quarterly OutperformanceLatest quarter Sales up 84.5% and Profit up 195.0%
- ●High Promoter HoldingPromoters hold 54.3% skin-in-the-game
- ●Promoter BuyingPromoters increased holdings by 44.33% QoQ
- ●Positive Free Cash FlowFCF has been positive for 3 consecutive years
Red Flags
- ●Earnings DeclineEPS (TTM) has contracted by 71.2% YoY
- ●Poor Capital ReturnsLow ROE of 0.9%
- ●Expensive ValuationTrading at a high P/E ratio of 690.2x
- ●Rising Receivables vs SalesReceivables grew 35.1% outpacing sales growth of 16.3%
- ●Promoter Pledging DetectedPledge activity recorded on 30-Sep-2025 16:12
Latest HEALTHCARE GLOB ENT News
What changed recently?
Recent events, corporate actions, and announcements.
HEALTHCARE GLOB. ENT. valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for HEALTHCARE GLOB. ENT., framed against the sector median so the premium or discount is obvious at a glance.
HEALTHCARE GLOB. ENT. trades at a P/E of 453.37× and P/B of 7.78×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
HEALTHCARE GLOB. ENT. technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for HEALTHCARE GLOB. ENT. — derived from the latest tape, not yesterday's close.
HEALTHCARE GLOB. ENT. last traded at ₹693.9 with an intraday range of ₹691.3–₹700.9 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹693.90| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 718.63 | +24.73 | +3.56% |
| R3 | 709.03 | +15.13 | +2.18% |
| R2 | 704.97 | +11.07 | +1.59% |
| R1 | 699.43 | +5.53 | +0.80% |
| PIVOT | 695.37 | 1.47 | 0.21% |
| CURRENT | 693.90 | — | — |
| S1 | 689.83 | -4.07 | -0.59% |
| S2 | 685.77 | -8.13 | -1.17% |
| S3 | 680.23 | -13.67 | -1.97% |
| S4 | 670.63 | -23.27 | -3.35% |
HCG is trading Below CPR, indicating Bearishness
CPR is Average
Day's range: ₹692–₹700.9
Trading Inside opening range
HEALTHCARE GLOB. ENT. financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for HEALTHCARE GLOB. ENT. — consolidated or standalone — with margins, YoY growth and key ratios inline.
HEALTHCARE GLOB. ENT. reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹10,356.35 Cr. and reported EPS of ₹0.92.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 2,223 | 2,545 ▲ 14.5% |
| Sales Growth YoY %Derived | 16.25% | 14.51% |
| Other Income | 35 | 25 ▼ 28.2% |
| Total Income | 2,258 | 2,570 ▲ 13.9% |
| 581 | 692 ▲ 19.2% | |
| Gross ProfitDerived | 1,642 | 1,853 ▲ 12.8% |
| Gross Margin %Derived | 73.88% | 72.80% |
| 1,255 | 1,387 ▲ 10.5% | |
| EBITDA (Operating Profit)Derived | 387 | 466 ▲ 20.3% |
| OPM %Derived | 17.42% | 18.30% |
| 366 | 376 ▲ 2.8% | |
| Profit Before Tax (PBT) | 56 | 25 ▼ 54.7% |
| 8 | 4 ▼ 49.1% | |
| Effective Tax %Derived | 14.47% | 16.26% |
| Total Profit for Period | 49 | 23 ▼ 53.3% |
| Less: Non-controlling Interests | 4 | 9 ▲ 104.1% |
| Net Profit (Owner's PAT)Derived | 44 | 14 ▼ 69.0% |
| Net Profit Margin %Derived | 2.00% | 0.54% |
| PAT Growth YoY %Derived | -7.75% | -69.02% |
| Earnings Per Share (EPS ₹) | 3.01 | 0.92 ▼ 69.4% |
| Diluted Shares Outstanding (Cr) | 15 | 15 ▲ 1.1% |
| Share of Profit from Associates/JVs | 1 | 1 ▲ 89.6% |
| Other Comprehensive Income (Net of Tax) | 2 | 5 ▲ 152.8% |
| Total Expenses (incl. D&A & Interest) | 2,201 | 2,545 ▲ 15.6% |
| Material Cost % of RevenueDerived | — | — |
| Employee Cost % of RevenueDerived | 15.90% | 14.87% |
| Other Cost % of RevenueDerived | 40.56% | 39.63% |
| Interest Coverage (x)Derived | 1.14x | 1.26x |
| Period | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 831 | 976 ▲ 17.5% | 1,096 ▲ 12.3% | 1,013 ▼ 7.5% | 1,398 ▲ 37.9% | 1,694 ▲ 21.2% | 1,912 ▲ 12.8% | 2,223 ▲ 16.3% | 2,545 ▲ 14.5% | |
| Sales Growth YoY %Derived | — | 17.50% | 12.26% | -7.50% | 37.93% | 21.22% | 12.85% | 16.25% | 14.51% | |
| Other Income | 13 | 10 ▼ 21.4% | 7 ▼ 30.7% | 17 ▲ 143.2% | 13 ▼ 25.3% | 13 ▲ 4.0% | 17 ▲ 28.5% | 35 ▲ 105.5% | 25 ▼ 28.2% | |
| Total Income | 843 | 986 ▲ 16.9% | 1,103 ▲ 11.8% | 1,030 ▼ 6.5% | 1,410 ▲ 36.9% | 1,708 ▲ 21.1% | 1,929 ▲ 13.0% | 2,258 ▲ 17.0% | 2,570 ▲ 13.9% | |
190 | 219 ▲ 15.2% | 240 ▲ 9.7% | 240 ▲ 0.2% | 355 ▲ 47.7% | 424 ▲ 19.5% | 475 ▲ 12.1% | 581 ▲ 22.1% | 692 ▲ 19.2% | ||
| Gross ProfitDerived | 641 | 757 ▲ 18.2% | 856 ▲ 13.0% | 773 ▼ 9.7% | 1,043 ▲ 34.9% | 1,270 ▲ 21.8% | 1,437 ▲ 13.1% | 1,642 ▲ 14.3% | 1,853 ▲ 12.8% | |
| Gross Margin %Derived | 77.16% | 77.60% | 78.11% | 76.29% | 74.61% | 74.97% | 75.14% | 73.88% | 72.80% | |
522 | 635 ▲ 21.6% | 684 ▲ 7.7% | 647 ▼ 5.4% | 805 ▲ 24.5% | 972 ▲ 20.7% | 1,107 ▲ 13.9% | 1,255 ▲ 13.4% | 1,387 ▲ 10.5% | ||
| EBITDA (Operating Profit)Derived | 119 | 123 ▲ 3.1% | 172 ▲ 40.5% | 127 ▼ 26.5% | 238 ▲ 88.0% | 299 ▲ 25.5% | 330 ▲ 10.3% | 387 ▲ 17.5% | 466 ▲ 20.3% | |
| OPM %Derived | 14.30% | 12.56% | 15.72% | 12.49% | 17.03% | 17.63% | 17.24% | 17.42% | 18.30% | |
125 | 155 ▲ 24.4% | 286 ▲ 84.6% | 185 ▼ 35.4% | 351 ▲ 89.6% | 267 ▼ 23.9% | 287 ▲ 7.5% | 366 ▲ 27.5% | 376 ▲ 2.8% | ||
| Profit Before Tax (PBT) | 29 | -22 ▼ 178.4% | -107 ▼ 377.4% | -228 ▼ 113.5% | 89 ▲ 139.1% | 45 ▼ 49.7% | 67 ▲ 50.0% | 56 ▼ 16.5% | 25 ▼ 54.7% | |
10 | -3 ▼ 124.4% | 6 ▲ 347.6% | -8 ▼ 222.1% | 49 ▲ 746.2% | 27 ▼ 44.2% | 26 ▼ 3.1% | 8 ▼ 69.2% | 4 ▼ 49.1% | ||
| Effective Tax %Derived | 35.83% | 11.16% | -5.79% | 3.31% | 54.76% | 60.70% | 39.21% | 14.47% | 16.26% | |
| Total Profit for Period | 17 | -31 ▼ 282.3% | -125 ▼ 306.3% | -221 ▼ 76.2% | 39 ▲ 117.6% | 18 ▼ 54.7% | 41 ▲ 134.5% | 49 ▲ 18.2% | 23 ▼ 53.3% | |
| Less: Non-controlling Interests | -4 | -6 ▼ 69.8% | -19 ▼ 208.6% | -28 ▼ 47.3% | -15 ▲ 46.4% | -12 ▲ 20.9% | -7 ▲ 41.8% | 4 ▲ 164.8% | 9 ▲ 104.1% | |
| Net Profit (Owner's PAT)Derived | 21 | -25 ▼ 220.9% | -107 ▼ 330.2% | -193 ▼ 81.3% | 54 ▲ 127.8% | 29 ▼ 45.4% | 48 ▲ 64.1% | 44 ▼ 7.7% | 14 ▼ 69.0% | |
| Net Profit Margin %Derived | 2.47% | -2.54% | -9.74% | -19.09% | 3.84% | 1.73% | 2.52% | 2.00% | 0.54% | |
| PAT Growth YoY %Derived | — | -220.86% | -330.20% | -81.33% | 127.77% | -45.39% | 64.08% | -7.75% | -69.02% | |
| Earnings Per Share (EPS ₹) | 2.23 | -2.66 ▼ 219.3% | -11.36 ▼ 327.1% | -14.58 ▼ 28.3% | 3.65 ▲ 125.0% | 1.99 ▼ 45.5% | 3.26 ▲ 63.8% | 3.01 ▼ 7.7% | 0.92 ▼ 69.4% | |
| Diluted Shares Outstanding (Cr) | 9 | 9 ▲ 1.2% | 9 ▲ 0.9% | 13 ▲ 41.3% | 15 ▲ 10.9% | 15 ▲ 0.1% | 15 ▲ 0.1% | 15 ▲ 0.1% | 15 ▲ 1.1% | |
| Share of Profit from Associates/JVs | -1 | -11 ▼ 684.3% | -12 ▼ 12.2% | -0 ▲ 97.1% | -1 ▼ 300.0% | -0 ▲ 98.6% | 0 ▲ 2050.0% | 1 ▲ 97.4% | 1 ▲ 89.6% | |
| Other Comprehensive Income (Net of Tax) | -0 | -3 ▼ 1786.7% | 0 ▲ 117.0% | 1 ▲ 22.9% | -2 ▼ 359.3% | -1 ▲ 13.7% | -0 ▲ 64.4% | 2 ▲ 483.0% | 5 ▲ 152.8% | |
| Total Expenses (incl. D&A & Interest) | 815 | 1,008 ▲ 23.8% | 1,210 ▲ 19.9% | 1,259 ▲ 4.1% | 1,321 ▲ 5.0% | 1,663 ▲ 25.8% | 1,862 ▲ 12.0% | 2,201 ▲ 18.2% | 2,545 ▲ 15.6% | |
| Material Cost % of RevenueDerived | — | — | — | — | — | — | — | — | — | |
| Employee Cost % of RevenueDerived | 18.99% | 18.91% | 18.99% | 19.33% | 16.72% | 16.24% | 16.12% | 15.90% | 14.87% | |
| Other Cost % of RevenueDerived | 43.87% | 46.14% | 43.40% | 44.46% | 40.87% | 41.11% | 41.78% | 40.56% | 39.63% | |
| Interest Coverage (x)Derived | 1.12x | 0.54x | 0.17x | -0.27x | 0.82x | 1.31x | 1.43x | 1.14x | 1.26x |
HEALTHCARE GLOB ENT segment analysis : revenue and profit mix.
Disclosed business segments at HEALTHCARE GLOB ENT with their share of revenue and profit, switchable between consolidated and standalone reporting.
HEALTHCARE GLOB ENT discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for HEALTHCARE GLOB. ENT..
Our AI distills the core fundamental drivers supporting HEALTHCARE GLOB. ENT., the risks that threaten it, and the quantitative conditions that could weaken the thesis.
HEALTHCARE GLOB. ENT.'s investment case rests on 0 positive markers and 1 flagged concerns drawn from the latest reported filings.
What you're getting.
No strengths or opportunities on record.
Key Risks.
SWOT generation temporarily unavailable due to model error. Bedrock invocation timeout
Flip Conditions.
Valuation risk. a P/E above 589 would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.00. Balance sheet risk re-prices growth multiples fast.
Return-quality risk. ROE below 8% would indicate weaker capital compounding.
HEALTHCARE GLOB. ENT. peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — HEALTHCARE GLOB. ENT. is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
HEALTHCARE GLOB. ENT. chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for HEALTHCARE GLOB. ENT. — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
HEALTHCARE GLOB. ENT. delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for HEALTHCARE GLOB. ENT. over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in HEALTHCARE GLOB. ENT. stood at 62.6% of traded volume, against a 20-day average of 55.6%.
HEALTHCARE GLOB ENT announcements: results, concalls, ratings, M&A.
Filings HEALTHCARE GLOB ENT sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
HEALTHCARE GLOB ENT files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 177 documents below.
Options to purchase securities
Healthcare Global Enterprises Limited has informed the Exchange about grant of Employee Stock Options under HealthCare Global Enterprises Limited-…
General Updates
Healthcare Global Enterprises Limited has informed the Exchange about Letter to Members of the Company containing weblink and path of Integrated…
Copy of Newspaper Publication
Healthcare Global Enterprises Limited has informed the Exchange about Copy of Newspaper Publication pertaining to dispatch of Notice of 28th Annual…
Shareholders meeting
Healthcare Global Enterprises Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 18, 2026 and…
Updates
Healthcare Global Enterprises Limited has informed the Exchange regarding 'Business Responsibility and Sustainability Report' for FY 2026.
Investor decks & rating reports.
HEALTHCARE GLOB ENT dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue HEALTHCARE GLOB ENT has declared, sequenced by announce and record date.
HEALTHCARE GLOB ENT corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
HEALTHCARE GLOB ENT insider trading: promoter and management activity.
Promoter, director and designated-employee transactions in HEALTHCARE GLOB ENT as reported to SEBI — buying and selling signals from the people who know the business best.
HEALTHCARE GLOB ENT insider activity below tracks 87 reported promoter, director and designated-employee transactions under SEBI Regulation 7(2).
| Insider | Category | Txn Date | Action | Quantity | Value (₹) | Price |
|---|---|---|---|---|---|---|
| Bharatsinh S Gadhavi | Insider | 30 Mar 2026 | buy | +13.9 K | ₹72.04 L | ₹519.40 |
| Bharatsinh S Gadhavi | Insider | 30 Mar 2026 | buy | +13.9 K | ₹72.04 L | ₹519.40 |
| Bharatsinh S Gadhavi | Insider | 30 Mar 2026 | buy | +13.9 K | ₹72.04 L | ₹519.40 |
| Bharatsinh S Gadhavi | Insider | 30 Mar 2026 | buy | +13.9 K | ₹72.04 L | ₹519.40 |
| Bharatsinh S Gadhavi | Insider | 30 Mar 2026 | buy | +13.9 K | ₹72.04 L | ₹519.40 |
| Bharatsinh S Gadhavi | Insider | 30 Mar 2026 | buy | +13.9 K | ₹72.04 L | ₹519.40 |
| CATALYST TRUSTEESHIP LIMITED | Insider | 27 Mar 2026 | buy | +14.7 K | ₹75.3 L | ₹512.00 |
| Hector Asia Holdings II Pte. Ltd. | Insider | 27 Mar 2026 | buy | +51.18 L | ₹262.04 Cr. | ₹512.00 |
| AAGNIKA AJAIKUMAR | Insider | 27 Mar 2026 | buy | +19.3 K | ₹98.56 L | ₹512.00 |
| ASMITHA AJAIKUMAR | Insider | 27 Mar 2026 | buy | +19.3 K | ₹98.56 L | ₹512.00 |
About HEALTHCARE GLOB. ENT.: business, sector, key facts.
What HEALTHCARE GLOB. ENT. does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
HEALTHCARE GLOB. ENT. operates in the Hospital industry under the Healthcare sector, listed as NSE: HCG, BSE: 539787.
HealthCare Global Enterprises Limited (HCG) is a leading provider of medical and healthcare services in India and internationally, specializing primarily in cancer care and fertility treatments. Their core business model revolves around delivering high-quality medical services across a range of specialties, with a significant focus on these two key areas.
In the realm of cancer care, HCG offers a comprehensive suite of diagnostic and treatment services. This includes radiation therapy, medical oncology (chemotherapy and other medical treatments), and surgical oncology. They also incorporate laboratory services and actively engage in research and development to improve cancer diagnosis, prognosis, and treatment outcomes. This integrated approach aims to provide patients with a holistic and advanced cancer care experience.
HCG's fertility services operate under the Milann brand, a well-established name in the field of reproductive medicine. Milann provides a wide spectrum of treatments, ranging from assisted reproductive technologies (ART) like in-vitro fertilization (IVF) to gynecological endoscopy and fertility preservation services. This comprehensive approach caters to a diverse range of patients' needs within the fertility space.
Beyond cancer and fertility, HCG operates multi-specialty hospitals under the HCG brand. These hospitals provide both inpatient and outpatient services covering a broad array of medical specialties, including cardiology, neurology, orthopedics, gastroenterology, urology, internal medicine, pulmonology, and critical care. This diversification allows HCG to offer a wider range of services and potentially attract a larger patient base.
In summary, HCG's business strategy combines specialized expertise in cancer and fertility with a broader multi-specialty hospital network. This diversified approach allows them to cater to a large and diverse patient population across multiple medical needs while maintaining a strong focus on advanced technologies and research to deliver high-quality medical care. Their integrated approach, spanning diagnostics, treatment, and research, positions them as a significant player within the Indian healthcare landscape and beyond.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- DR AGARWALS HEALTH CARE L (AGARWALEYE) Share PricePeer
- APOLLO HOSPITALS ENTER L (APOLLOHOSP) Share PricePeer
- ARTEMIS MED SERVICE (ARTEMISMED) Share PricePeer
- ASTER DM QUALITY CARE (ASTERDM) Share PricePeer
- FORTIS HEALTHCARE (FORTIS) Share PricePeer
- Other overvalued NSE stocksScreener
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about HEALTHCARE GLOB. ENT. (HCG).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of HEALTHCARE GLOB. ENT. (HCG)?
The current share price of HEALTHCARE GLOB. ENT. (HCG) is ₹693.90. Today, the stock has declined by ₹7.00 (1%), trading in a range of ₹691.30 to ₹700.90. The stock opened at ₹700.90 with a trading volume of 44,421 shares.
02Is HEALTHCARE GLOB. ENT. stock a good investment for long-term?
HEALTHCARE GLOB. ENT. can be considered for long-term investment based on several factors. The company has a market capitalization of ₹10,356.35 Cr., P/E ratio of 453.37, ROE of 0.91%, and ROCE of 5.66%. The dividend yield stands at 0%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of HEALTHCARE GLOB. ENT. stock?
The 52-week high price of HEALTHCARE GLOB. ENT. (HCG) is ₹804.65, while the 52-week low is ₹513.30. Currently trading at ₹693.90, the stock is 35.18% above its 52-week low and 13.76% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy HEALTHCARE GLOB. ENT. stock at the current price?
Whether to buy HEALTHCARE GLOB. ENT. stock at ₹693.90 depends on multiple factors. The stock is currently trading with a P/E ratio of 453.37 and P/B ratio of 7.78. Today's performance shows a loss of 1%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of HEALTHCARE GLOB. ENT. and when is the next dividend?
HEALTHCARE GLOB. ENT. offers a dividend yield of 0%, which means for every ₹100 invested at the current price of ₹693.90, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of HEALTHCARE GLOB. ENT.?
HEALTHCARE GLOB. ENT.'s key financial metrics include: P/E Ratio: 453.37, P/B Ratio: 7.78, ROE: 0.91%, ROCE: 5.66%, Dividend Yield: 0%, EPS: ₹0.92, Book Value: ₹94.45, and Debt-to-Equity: 0.35. The company's market cap stands at ₹10,356.35 Cr.. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is HEALTHCARE GLOB. ENT. stock performing today in the market?
HEALTHCARE GLOB. ENT. stock opened at ₹700.90 and is currently trading at ₹693.90, showing a decline of ₹7.00 (1%). The intraday high is ₹700.90 and low is ₹691.30. The trading volume stands at 44,421 shares, indicating moderate market participation today.
08What is the P/E ratio of HEALTHCARE GLOB. ENT. and what does it indicate?
HEALTHCARE GLOB. ENT. has a Price-to-Earnings (P/E) ratio of 453.37, which means investors are willing to pay 453.37 for every ₹1 of earnings. With an EPS of ₹0.92, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about HEALTHCARE GLOB. ENT. (HCG) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.